Study of Botulinum Toxin Type A (BOTOX®) to Treat Urinary Incontinence From Neurogenic Detrusor Overactivity in Belgium

N/ACompletedNCT02072928

Allergan55 enrolled

Overview

This study will evaluate the impact of BOTOX® treatment on anticholinergic drug use in patients with urinary incontinence from Neurogenic Detrusor Overactivity (NDO) due to spinal injury or Multiple Sclerosis (MS) who are prescribed BOTOX® as standard of care in clinical practice.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Urinary Incontinence

Interventions

botulinum toxin Type ABIOLOGICAL

botulinum toxin Type A (BOTOX®) prescribed as standard of care in clinical practice.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients prescribed BOTOX® for urine incontinence from NDO due to spinal injury or MS as standard of care in clinical practice in Belgium * Previous treatment with anticholinergic drugs ineffective * Last BOTOX® treatment ≥18 months. Exclusion Criteria: * Diagnosis of urinary incontinence less than 9 months. * No anticholinergic drug use in the last 9 months.

Locations (6)

UZA

Edegem, Belgium

CHU de Liège

Esneux, Belgium

UZ Gent

Ghent, Belgium

Centre Hospitalier Regional de Huy

Huy, Belgium

UZ Leuven

Outcomes

Primary Outcomes

Change From Baseline in Anticholinergic Drug Use

Anticholinergic drug use was collected the 9 months before the baseline Botox® treatment and the 9 months following the baseline Botox® treatment. Total anticholinergic drug use in the 9 months following the baseline Botox® treatment is noted.

Time frame: Baseline, 9 Months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.